Company Profile · Healthcare

Bruker Corporation

BRKR · US
Industry
Life Science Tools
Exchange
US
Country
USA
IPO date
Aug 4, 2000
Employees
11,085
Website
www.bruker.com
Current Price
$54.73
Live · Jun 18, 2026
Fair Buy
≤ $48
Margin-of-safety entry
Baillie Growth Score
41/100
Weak
Intrinsic Value · Three-Tier Range Current price $54.73 Live · Within the fair intrinsic-value range

Composite valuation range · conservative $35–$45 / fair $48–$60 / optimistic $68–$85. At $54.73, Within the fair intrinsic-value range.

At publication $59.97 (Jun 4, 2026)

Research on this stock
Bruker Corporation
BRKR · US
Watch
Bruker Zen Horizon Research: A Hidden Champion in Scientific Instruments, but Organic Growth Is Receding and Valuation Has Priced In the Recovery

Bruker is a hidden global champion in high-end scientific analytical instruments, with a near-oligopoly position in NMR. Organic growth has turned negative for consecutive periods, reported growth is being held up by acquisitions and FX, GAAP earnings have swung to a loss, and the profit recovery depends heavily on cost execution after a roughly 70% one-month surge left the current price of $59.97 above the average sell-side target by 16% and forward PE at about 27-28x near the top of peers. Research rating Watch: a high-quality moat business that needs either a confirmed organic inflection or a pullback toward roughly $48 to restore margin of safety.

Life Science Tools Baillie 41 Jun 4, 2026
About the company

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.

Financial snapshot
Market cap$8.33B
Revenue (TTM)$3.46B
EBITDA$488.7M
Profit margin-0.34%
ROE-0.43%
Forward P/E15.22
PEG1.52
EPS-$0.24
Dividend yield0.36%
52-week range$28.41 – $64.54
Analyst target$53.25
Analyst rating3.9 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.